ABIVAX Société Anonyme ranks below the peer group median, with growth as the main structural strength. That creates a tension: current price behavior looks stronger than the structural profile would suggest.
Discounted for a Reason: Abivax’s Losses Eclipse Growth
52w drawdown 0.0% · 21d vs sector +58.9%
Peer-relative scores, weakest to strongest
Abivax is a biotech company developing treatments for inflammatory and viral diseases, with a primary focus on ulcerative colitis. The company’s prospects depend on the success of its clinical programs and regulatory milestones.
Abivax stays discounted despite growth because losses dominate the picture. Even with revenue growth of 35.2%, the company’s operating margin at -4183.7% shows that the market prices the stock at a steep discount, reflecting the overwhelming scale of ongoing losses rather than rewarding expansion. As a biotech focused on ulcerative colitis, Abivax’s trajectory depends on the outcome of individual clinical programs and regulatory milestones, which increases the risk profile. The market withholds rerating, and every clinical setback leads to significant share price declines. Growth is outweighed by the magnitude of losses.
Break down ABVX.PA's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.